PROGLUMIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H26N2O4
Molecular Weight	334.41
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1

InChI

InChIKey=DGMKFQYCZXERLX-UHFFFAOYSA-N

InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)

HIDE SMILES / InChI

Molecular Formula	C18H26N2O4
Molecular Weight	334.41
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2862828
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2299627 | https://www.ncbi.nlm.nih.gov/pubmed/2741440 | https://www.drugs.com/international/proglumide.html | https://goo.gl/d51Yn7 | https://www.ncbi.nlm.nih.gov/pubmed/3651819 | https://www.ncbi.nlm.nih.gov/pubmed/2994583

Proglumide is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application. An interesting side effect of proglumide is that it enhances the analgesia produced by opioid drugs, and can prevent or even reverse the development of tolerance to opioid drugs. This can make it a useful adjuvant treatment to use alongside opioid drugs in the treatment of chronic pain conditions such as cancer, where opioid analgesics may be required for long periods and development of tolerance reduces clinical efficacy of these drugs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cholecystokinin A receptor 7 Target ID: CHEMBL2871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2299627	Antagonist 2849		250.0 µM [IC50]
Cholecystokinin B receptor 9 Target ID: CHEMBL298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2299627	Antagonist 2849		900.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Peptic ulcer 72 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2741440	Primary		Approved 8583	Proglumide Approved Use Unknown

C_max

Value	Dose	Analyte	Population
7847 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
9721 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
10635 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
43300 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
30400 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
31800 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35336003/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	PROGLUMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED

Doses

Dose	Population	Adverse events
1200 mg 1 times / day multiple, oral Studied dose Dose: 1200 mg, 1 times / day Route: oral Route: multiple Dose: 1200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26518/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26518/	Sources: https://pubmed.ncbi.nlm.nih.gov/26518/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP2E1 1060 CYP2A6 879 OATP1B1 1079 CYP1A2 2153 OATP1B3 961 CYP19A1 429 OATP2B1 157 P-gp 1741	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/4922#section=BioAssay-Results Page: 9.0	inconclusive
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDMxNjU2MSJ9fQ==	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDMxNjU2MSJ9fQ==	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDMxNjU2MSJ9fQ==	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDMxNjU2MSJ9fQ==	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMzE2NTYxIn19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDMxNjU2MSJ9fQ==	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMzE2NTYxIn19	no [IC50 >10 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/4922#section=BioAssay-Results Page: 344.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/4922#section=BioAssay-Results Page: 372.0	no
OATP2B1 162	inhibitor 4027 Sources: https://edoc.unibas.ch/84877/	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDMxNjU2MSJ9fQ==	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDMxNjU2MSJ9fQ==	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/4922#section=BioAssay-Results Page: 371 \| 374	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMzE2NTYxIn19

PubMed

Title	Date	PubMed
Estrogen receptor alpha-induced cholecystokinin type A receptor expression in the female mouse pituitary.	2007-12	18000302
Effect of intravenous infusion of proglumide on ruminal motility in conscious sheep (Ovis aries).	2007-11	17279465
The effect of luminal ghrelin on pancreatic enzyme secretion in the rat.	2007-10-04	17462749
Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors.	2007-10	17652263
Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake.	2007-10	17634201
Cholecystokinin-8s excites identified rat pancreatic-projecting vagal motoneurons.	2007-08	17569742
Vagally mediated, nonparacrine effects of cholecystokinin-8s on rat pancreatic exocrine secretion.	2007-08	17569741
The inhibitory effect of proglumide on meal-induced insulin sensitization in rats.	2007-07	17570243
Activation of spinal cholecystokinin and neurokinin-1 receptors is associated with the attenuation of intrathecal morphine analgesia following electroacupuncture stimulation in rats.	2007-06	17558184
The use of animal models to study bacterial translocation during acute pancreatitis.	2007-05	17468930
Enterostatin (APGPR) enhances memory consolidation in mice.	2007-03	17175068
Peripheral participation of cholecystokinin in the morphine-induced peripheral antinociceptive effect in non-diabetic and diabetic rats.	2007-03	17157334
Mechanism of the induction of brain c-Fos-positive neurons by lipid absorption.	2007-01	16990492
The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect.	2006-11-15	17108175
Gastrin induces leukocyte-endothelial cell interactions in vivo and contributes to the inflammation caused by Helicobacter pylori.	2006-11	17015411
Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen.	2006-10-27	17069643
The combined effects of proglumide and fluorouracil on the growth of murine Colon 38 cancer cells in vitro.	2006-07-06	16821214
Caerulein-induced acute pancreatitis in mice that constitutively overexpress Reg/PAP genes.	2006-05-15	16700916
Cholecystokinin hyperresponsiveness in functional dyspepsia.	2006-05-07	16718754
Naloxone, not proglumide or MK-801, alters effects of morphine preexposure on morphine-induced taste aversions.	2006-05	16777201
Involvement of cholecystokinin in peripheral nociceptive sensitization during diabetes in rats as revealed by the formalin response.	2006-05	16527403
Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes".	2006-04-20	16610788
Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.	2006-03	16552340
[Receptor mechanisms underlying the modulation of lipopolysaccharide-induced nuclear factor-kappaB expression in vascular endothelial cells by cholecystokinin octapeptide].	2006-03	16524505
Estrogen and CCK1 receptor modification of mu-opioid receptor binding in the cortex of female rats.	2006-02-16	16472782
Activation of neural cholecystokinin-1 receptors induces relaxation of the isolated rat duodenum which is reduced by nitric oxide synthase inhibitors.	2006-02	16470315
[Effects of gastrin receptor antagonist and cyclooxygenase-2 inhibitor on proliferation and apoptosis of gastric cancer cell].	2006-01-24	16677505
Effects of amylin on feeding of goldfish: interactions with CCK.	2006-01-15	16239037
CCK1 antagonists: are they ready for clinical use?	2006	16699265
Effect of cholecystokinin octapeptide on diacylglycerol-PKC signaling pathway in rat pulmonary interstitial macrophages stimulated by lipopolysaccharide.	2005-12	16297350
Role of cholecystokinin in appetite control and body weight regulation.	2005-11	16246215
Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin.	2005-10	16150104
Cholecystokinin octapeptide increases spontaneous glutamatergic synaptic transmission to neurons of the nucleus tractus solitarius centralis.	2005-10	16093341
Cholecystokinin1 receptors mediate the increase in Fos-like immunoreactivity in the rat myenteric plexus following intestinal oleate infusion.	2005-09-15	16098547
Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity.	2005-09	15879057
Cholecystokinin octapeptide improves cardiac function by activating cholecystokinin octapeptide receptor in endotoxic shock rats.	2005-06-14	15948246
Long-term effects of proglumide on resection of cardiac adenocarcinoma.	2005-05-07	15849809
Proopiomelanocortin neurons in nucleus tractus solitarius are activated by visceral afferents: regulation by cholecystokinin and opioids.	2005-04-06	15814788
Proglumide attenuates experimental colitis in rats.	2005-03	15816362
Cholecystokinin inhibits evoked inhibitory postsynaptic currents in the rat nucleus accumbens indirectly through gamma-aminobutyric acid and gamma-aminobutyric acid type B receptors.	2005-02-01	15605383
Effects of juice from Morinda citrifolia (Noni) on gastric emptying in male rats.	2004-12-31	15803749
[New aspects of pharmaco-therapy for acute pancreatitis].	2004-11	15552891
Involvement of cholecystokinin in the opioid tolerance induced by dipyrone (metamizol) microinjections into the periaqueductal gray matter of rats.	2004-11	15494191
Use of a hepta-Tyr antibiotic modified silica stationary phase for the enantiomeric resolution of D,L-loxiglumide by electrochromatography and nano-liquid chromatography.	2004-10-08	15532580
Effect of lipopolysaccharide on expression and characterization of cholecystokinin receptors in rat pulmonary interstitial macrophages.	2004-10	15456538
Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.	2004-10	15331911
Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors.	2004-09-30	15327914
Suppression of food intake by GI fatty acid infusions: roles of celiac vagal afferents and cholecystokinin.	2004-08	15234586
Differential contribution of cholecystokinin receptors to stress-induced modulation of seizure and nociception thresholds in mice.	2004-06	15219760
The effects of an essential fatty acid compound and a cholecystokinin-8 antagonist on iron deficiency induced anorexia and learning deficits.	2004-04	15279494

Patents

Sample Use Guides

In Vivo Use Guide

PO 400 mg 2-4 times/day, up to 800 mg 3 times/day. IV/IM 400-800 mg/day.

Route of Administration: Other

In Vitro Use Guide

The cell lines SW 403, Ls 174 T and Lovo (provided by the Institute for Immunbiology, Freiburg) were cultured in Dulbecco's or RPMI medium, with 10% fetal calf serum and antibiotics. The effects of proglumide (Milid, Opfermann, Bergisch-Gladbach) were estimated by cell count (Neubauer) and measurement of incorporation of [3H]thymidine (Amersham-Buchler, Braunschweig). Cells were counted after trypsinization (0.03%, 37 ~ C, 30rain in Hank's EDTA, Gibco) at the second and eighth day of culture. After cell harvesting, [3H]thymidine incorporation was estimated by beta counting equipment. Six-well plates containing 4 x 104 cells were used in each cellcounting experiment; 96-well plates were used for each [3H]thymidine-incorporation experiment. Medium was changed every second day and cell viability was proved by eosin staining. Gastrin and CEA concentrations were estimated by radioimmunoassay (Travenol, M/inchen; Abbott, Wiesbaden) in cell-culture medium. For synchronization the cells were incubated for 48 h in Dulbecco's or RPMI medium without fetal calf serum (37 ~ C). The cells were then cooled to 4 ~ C for 24 h and fetal calf serum (10%) and thymidine (2 nmol) were added. About 70%-75% cells survived this procedure, as has been shown by eosin staining. After 24 h the cells were incubated with various concentrations of gastrin, pentagastrin or proglumide.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:53:23 GMT 2025` Edited by `admin` on `Wed Apr 02 09:53:23 GMT 2025`
Record UNII	EPL8W5565D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROGLUMIDE

Official Name

English

NULSA

Preferred Name

English

PROGLUMIDE [MI]

Common Name

English

CR-242

Code

English

ULCUTIN

Brand Name

English

PROGLUMIDE [JAN]

Common Name

English

Proglumide [WHO-DD]

Common Name

English

MILID

Brand Name

English

XYLAMIDE

Brand Name

English

GASTROTOPIC

Brand Name

English

BINOSIDE

Brand Name

English

MIDELID

Brand Name

English

(±)-4-BENZAMIDO-N,N-DIPROPYLGLUTARAMIC ACID

Systematic Name

English

PROGLUMIDE [MART.]

Common Name

English

proglumide [INN]

Common Name

English

W-5219

Code

English

PROMID

Brand Name

English

4-(BENZOYLAMINO)-5-(DIPROPYLAMINO)-5-OXOPENTANOIC ACID

Systematic Name

English

XYDE

Brand Name

English

PENTANOIC ACID, 4-(BENZOYLAMINO)-5-(DIPROPYLAMINO)-5-OXO-, (±)-

Common Name

English

DL-PROGLUMIDE

Common Name

English

PROGLUMIDE [USAN]

Common Name

English

NSC-757841

Code

English

GLUTARAMIC ACID, 4-BENZAMIDO-N,N-DIPROPYL-, DL-

Common Name

English

Classification Tree Code System Code

WHO-ATC

A02BX06